Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2024; 30(37): 4083-4086
Published online Oct 7, 2024. doi: 10.3748/wjg.v30.i37.4083
Current approaches to the management of jejunal variceal bleeding at the site of hepaticojejunostomy after pancreaticoduodenectomy
Dmitry Victorovich Garbuzenko
Dmitry Victorovich Garbuzenko, Department of Faculty Surgery, South Ural State Medical University, Chelyabinsk 454092, Russia
Author contributions: Garbuzenko DV contributed to the conception, design, acquisition, analysis, interpretation of data, wrote the manuscript and approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Dmitry Victorovich Garbuzenko, DSc, MD, PhD, Professor, Department of Faculty Surgery, South Ural State Medical University, 64 Vorovskogo Street, Chelyabinsk 454092, Russia. garb@inbox.ru
Received: April 28, 2024
Revised: August 20, 2024
Accepted: September 9, 2024
Published online: October 7, 2024
Processing time: 150 Days and 21.7 Hours
Core Tip

Core Tip: Pharmacotherapy, endoscopic methods, transcatheter embolization of veins feeding the afferent loop of the jejunum, portal vein stenting and surgical interventions can be used to treat jejunal variceal bleeding at the site of hepaticojejunostomy after pancreaticoduodenectomy. Nevertheless, the optimal management strategy has not yet been established, which is due to the lack of randomized controlled trials involving a large cohort of patients necessary for their development.